Propensity-matched comparison of balloon-expandable and self-expanding valves for transcatheter aortic valve replacement in a Chinese population
Wen-Bin Ou-Yang,Wei Wang,Jie Dong,Yong-Quan Xie,Jun-Yi Wan,Zi-Qi Yue,Shou-Zheng Wang,Hong Meng,Xu Wang,Dong-Hui Xu,Feng-Wen Zhang,Jing Dong,Xiang-Bin Pan,Ge-Jun Zhang
DOI: https://doi.org/10.21037/atm-21-6637
IF: 3.616
2022-01-01
Annals of Translational Medicine
Abstract:Background: Balloon-expandable valves (BEV) and self-expanding valves (SEV) for transcatheter aortic valve replacement (TAVR) have shown promising results in Western populations. Herein, we comparatively evaluated their hemodynamics and early clinical outcomes in a Chinese population.Methods: One hundred seventy-eight patients with symptomatic aortic stenosis who had undergone transfemoral TAVR using SEV (n=153; Venus-A, 97; VitaFlow, 56) or BEV (n=25; Sapien3) from September 2020 to April 2021 were retrospectively enrolled, and 25 pairs were propensity-score matched for 10 baseline variables. The primary study outcomes were aortic valve hemodynamics and postoperative complications at discharge and 3-month follow-up.Results: TAVR was successful in all patients. Compared with SEV group, the BEV group had similarly distributed baseline characteristics, procedural time, hospital stay, new pacemaker implantation, and paravalvular regurgitation grade. We also observed that the BEV group had lower rates of balloon pre-dilation (60% <i>vs.</i> 92%, P=0.018), post-dilation (0 <i>vs.</i> 20%, P=0.050) and second valve implantation (0 <i>vs.</i> 24%, P=0.022); higher mean transaortic gradient (14.3±6.1 <i>vs.</i> 10.8±4.9, P=0.030) and proportion of patients with elevated gradients (20% <i>vs.</i> 0, P=0.050) at discharge; and similar rehospitalization, mean transaortic gradient, new pacemaker implantation, and paravalvular regurgitation grade than the SEV group at the 3-month follow-up. There were no deaths in either group. However, the proportion of patients with elevated gradients in SEV group was higher at 3 months than before discharge (24% <i>vs.</i> 0, P=0.022).Conclusions: BEV and SEV for transfemoral TAVR appear comparably safe and effective, with high device success and favorable 3-month clinical outcomes. However, the transaortic gradient and new pacemaker implantation in the SEV group increased during follow-up, warranting larger studies with longer-term follow-up.
oncology,medicine, research & experimental